Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

被引：0
作者：
Inzucchi, Silvio E. [1 ]
Wanner, Christoph [2 ]
Lachin, John M. [3 ]
Fitchett, David [4 ]
Bluhmki, Erich [5 ]
Hantel, Stefan [5 ]
Mattheus, Michaela [6 ]
Devins, Theresa [7 ]
Johansen, Odd Erik [8 ]
Woerle, Hans Juergen [8 ]
Broedl, Uli C. [9 ]
Zinman, Bernard [10 ,11 ,12 ]
机构：
[1] Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT USA
[2] Wurzburg Univ Clin, Div Nephrol, Dept Med, Wurzburg, Germany
[3] George Washington Univ, Biostat Unit, Rockville, MD USA
[4] St Michaels Hosp, Div Cardiol, Toronto, ON M5B 1W8, Canada
[5] Boehringer Ingelheim Pharma GmbH & Co KG, Global Biometr & Datamanagement, Biberach, Germany
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Global Biometr & Datamanagement, Ingelheim, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Clin Operat, Ridgefield, CT USA
[8] Boehringer Ingelheim Norway KS, Therapeut Area Metab, Asker, Norway
[9] Boehringer Ingelheim Pharma GmbH & Co KG, Therapeut Area Metab, Ingelheim, Germany
[10] Mt Sinai Hosp, Lunenfeld Tanenbaum Rsch Inst, Toronto, ON M5G 1X5, Canada
[11] Mt Sinai Hosp, Div Endocrinol, Toronto, ON M5G 1X5, Canada
[12] Univ Toronto, Toronto, ON, Canada
来源：
CIRCULATION | 2015年 / 132卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
20238
引用
收藏
页码：2271 / 2271
页数：1
相关论文
共 50 条
  • [31] Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
    Men, Peng
    Liu, Tianbi
    Zhai, Suodi
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 2823 - 2831
  • [32] Letter by Tampaki et al Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk"
    Tampaki, Ekaterini Christina
    Tampakis, Athanasios
    Gurke, Lorenz
    STROKE, 2017, 48 (09) : E255 - E255
  • [33] Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
    Kapoor, Karan
    George, Praveen
    Miller, Michael
    CARDIOLOGY, 2016, 135 (02) : 108 - 126
  • [34] Design of the empagliflozin cardiovascular outcome event trial in type 2 diabetes mellitus
    Inzucchi, S. E.
    Zinman, B.
    Lachin, J. M.
    Wanner, C.
    Ferrari, R.
    Bluhmki, E.
    Hantel, S.
    Johansen, O.
    Woerle, H. -J.
    Broedl, U. C.
    DIABETOLOGIA, 2013, 56 : S378 - S378
  • [35] Cardiovascular risk in patients with newly diagnosed type 2 diabetes mellitus
    Fuadal-Saraj
    McAteer, S
    Galvin, J
    Keelan, E
    Fitzgerald, D
    Cawood, T
    Sreenan, SK
    DIABETES, 2005, 54 : A172 - A172
  • [36] Predictor for cardiovascular risk in patients with type-2 diabetes mellitus
    Azharuddin, Md
    Kapur, Prem
    Mishra, Ritu
    Saleem, Shakir
    Gupta, Ashok Kumar
    Adil, Mohammad
    Sharma, Manju
    CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH, 2021, 12
  • [37] Prevention of cardiovascular risk in patients with type 2 diabetes mellitus with aspirin
    Duly-Bouhanick, B
    Menard, S
    Hadjadj, S
    Soares-Barbosa, S
    Plun-Favreau, J
    Guilloteau, G
    PRESSE MEDICALE, 2001, 30 (02): : 87 - 91
  • [38] ASSESSMENT OF CARDIOVASCULAR DISEASES RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Jose, C.
    VALUE IN HEALTH, 2017, 20 (05) : A351 - A351
  • [39] Evaluation of Residual Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus
    Reingold, Jason S.
    Nasir, Khurram
    Patel, Neel R.
    Pourfarzib, Ray
    Winegar, Deborah
    DIABETES, 2013, 62 : A614 - A615
  • [40] The validation of cardiovascular risk scores for patients with type 2 diabetes mellitus
    van der Leeuw, J.
    van Dieren, S.
    Beulens, J. W. J.
    Boeing, H.
    Spijkerman, A. M. W.
    van der Graaf, Y.
    van der A, D. L.
    Noethlings, U.
    Visseren, F. L. J.
    Rutten, G. E. H. M.
    Moons, K. G. M.
    van der Schouw, Y. T.
    Peelen, L. M.
    HEART, 2015, 101 (03) : 222 - 229
12345